Examining the relationship between adherence and satisfaction with antidepressant treatment

Abstract

BackgroundAdherence to antidepressant treatment is an essential step in the management of patients with major depressive disorder, and several factors can contribute to antidepressant nonadherence. Evidence supports the hypothesis that patient treatment satisfaction will result in improved adherence; therefore, the aim of this study was to investigate the relationship between patient treatment satisfaction and adherence to antidepressants, and the role of patient beliefs toward medication in patient treatment satisfaction.MethodsThis was an observational, nonexperimental survey of all patients attending Al Amal Psychiatric Hospital (500 beds) in Riyadh, Saudi Arabia. Medication adherence was assessed using the eight-item Morisky Medication Adherence Scale (MMAS-8), and treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4).ResultsA total of 403 patients met the inclusion criteria; 50.4% were females; participant age ranged from 18 to 60 years; and 16 % of the patients reported side effects after using antidepressants. Both males and females reported high treatment satisfaction rates: – 79.21% (standard deviation [SD] 8.52) and 86.55% (SD 14.34), respectively – with statistically significant associations found for female sex, older age, and three or more physician visits per year. Adherence to antidepressants was associated with treatment satisfaction with the antidepressants, with a direct positive correlation.ConclusionThe results of this study showed high treatment satisfaction scores among patients in Saudi Arabia with major depressive disorder, which correlated with adherence and patient beliefs about the necessity of treatment. This finding has improved the understanding of the role of patient beliefs, which can help caregivers and other stakeholders to improve satisfaction with antidepressants.

Treatment satisfaction and adherence to medications among multiple sclerosis patients in Saudi Arabia

“…Patients' medication adherence was assessed using the Arabic version of the eight-item Morisky Medication Adherence Scale (MMAS-8) [14][15][16]. This version is a well-validated instrument [17]. The total score of the scale ranges from 0 to 8, with higher scores reflecting higher adherence.…”

Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression

“…Regarding effectiveness outcomes, the patients’ satisfaction with treatment with paroxetine CR, as well as their treatment preferences, were evaluated with the objective measures frequently used in clinical studies, as those are known to be positively associated with improved adherence or persistence. 15 – 17 The interim analysis of safety and effectiveness in this study has already been reported in patients who completed the study by the end of January 2013 (safety population, n=1,150). 18…”

Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder

“…Previous meta-analyses of clinical trial data, 12 however, have not examined healthcare utilizations and costs for these compounds 63,64 . Furthermore, patients enrolled in RCTs may have higher average adherence than those seen in the clinical office practice setting, and these adherence differences have been known to impact clinical effectiveness and economic outcomes [65][66][67][68][69] .…”